Background T-cell–redirecting therapies, such as bispecific antibodies and chimeric antigen
receptor T-cells, exploit the cytotoxic capabilities of the immune system to destroy cells …

Patients with multiple myeloma (MM) were among the groups impacted more severely by the
COVID-19 pandemic, with higher rates of severe disease and COVID-19-related mortality …

Teclistamab (Tec) is a first-in-class BCMA X CD3 bispecific T-cell engager antibody
approved for treating multiple myeloma progressing after at least 4 lines of therapy. The …

Patients with relapsed/refractory multiple myeloma (RRMM) that are refractory to the five
most active anti-MM drugs, so-called penta-refractory MM, have historically had dismal …

Recently, several bispecific antibodies (BsAbs) have been approved for the treatment of
relapsed multiple myeloma (MM) after early phase trials in heavily pre-treated patients …

Simple Summary Multiple myeloma (MM) represents the second most common
hematological malignancy, but its diagnosis can be significantly delayed since symptoms …

Introduction The rise of recent novel therapies teclistamab, elranatamab, and talquetamab
for the treatment of relapsed/refractory multiple myeloma (RRMM) is a rapidly evolving area …

Multiple myeloma remains an incurable disease, despite the development of numerous drug
classes and combinations that have contributed to improved overall survival …

Objective: To review the therapeutic profile of elranatamab, a novel bispecific T-cell-
redirecting therapy, in treating relapsed or refractory (R/R) multiple myeloma (MM). Data …

The treatment options for multiple myeloma (MM) have undergone significant transformation
with the advent of immunotherapy. Novel therapies that focus on tumor antigens now drive …